KP 910
Alternative Names: KP-910Latest Information Update: 15 Jan 2024
At a glance
- Originator Kaken Pharmaceutical
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neuropathic pain
Most Recent Events
- 04 Aug 2023 Phase-I clinical trials in Neuropathic pain (In volunteers, In adults) in Japan (PO) (jRCT2071230041)